Adefovir

Adefovir

Clinical data
Trade names	Hepsera
AHFS/Drugs.com	Monograph
Pregnancy category	AU: B3
Routes of administration	Oral
ATC code	J05AF08 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	59%
Protein binding	<4%
Elimination half-life	7.5 hours
Excretion	Urine
Identifiers
IUPAC name {[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid
CAS Number	106941-25-7 N
PubChem CID	60172
DrugBank	DB00718 Y
ChemSpider	54252 Y
UNII	6GQP90I798
KEGG	D02768 Y
ChEBI	CHEBI:2469 Y
ChEMBL	ChEMBL484 Y
NIAID ChemDB	028595
CompTox Dashboard (EPA)	DTXSID6046214
ECHA InfoCard	100.106.235
Chemical and physical data
Formula	C8H12N5O4P
Molar mass	273.189 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=P(O)(O)COCCn1c2ncnc(c2nc1)N
InChI InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16) Y Key:SUPKOOSCJHTBAH-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Adefovir is a prescription medicine used to treat (chronic) infections with hepatitis B virus. A prodrug form of adefovir was previously called bis-POM PMEA, with trade names Preveon and Hepsera. It is an orally administered nucleotide analog reverse-transcriptase inhibitor (ntRTI). It can be formulated as the pivoxil prodrug adefovir dipivoxil.